OverviewSuggest Edit

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines. The company aims to transform and simplify care for people with life-threatening illnesses. Its portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

TypePublic
Founded1987
HQFoster City, CA, US
Websitegilead.com
Employee Ratings3.8
Overall CultureB+

Latest Updates

Employees (est.) (Jan 2020)11,800(+8%)
Job Openings701
Revenue (FY, 2020)$24.7 B(+10%)
Share Price (Jun 2021)$68.8
Cybersecurity ratingFMore

Key People/Management at Gilead Sciences

Daniel O’Day

Daniel O’Day

Chairman and Chief Executive Officer
Andrew Dickinson

Andrew Dickinson

Chief Financial Officer
William A. Lee

William A. Lee

Executive Vice President, Research
Flavius Martin

Flavius Martin

Executive Vice President, Research
Jyoti Mehra

Jyoti Mehra

Executive Vice President, Human Resources
Johanna Mercier

Johanna Mercier

Chief Commercial Officer
Show more

Gilead Sciences Office Locations

Gilead Sciences has offices in Foster City, El Segundo, Emeryville, Miami and in 41 other locations
Foster City, CA, US (HQ)
333 Lakeside Dr
El Segundo, CA, US
2355 Utah Ave
Emeryville, CA, US
5858 Horton St #240
Miami, FL, US
5200 Blue Lagoon Dr #450
Oceanside, CA, US
4049 Avenida De La Plata
San Dimas, CA, US
650 Cliffside Dr
Show all (45)

Gilead Sciences Financials and Metrics

Gilead Sciences Revenue

Embed Graph
View revenue for all periods
Gilead Sciences's revenue was reported to be $24.69 b in FY, 2020
USD

Revenue (Q1, 2021)

6.4b

Gross profit (Q1, 2021)

5.1b

Gross profit margin (Q1, 2021), %

78.8%

Net income (Q1, 2021)

1.7b

EBIT (Q1, 2021)

2.9b

Market capitalization (11-Jun-2021)

86.6b

Closing stock price (11-Jun-2021)

68.8

Cash (31-Mar-2021)

4.1b

EV

112.7b
Gilead Sciences's current market capitalization is $86.6 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

26.1b22.1b22.4b24.7b

Revenue growth, %

(15%)1%

Cost of goods sold

4.4b4.9b4.7b4.6b

Gross profit

21.7b17.3b17.8b20.1b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

6.5b7.1b6.5b5.1b5.6b5.6b5.3b5.7b5.6b5.5b5.1b6.6b6.4b

Cost of goods sold

957.0m1.1b1.0b1.0b1.2b1.1b957.0m1.0b1.0b969.0m1.1b1.1b1.4b

Gross profit

5.5b6.0b5.5b4.1b4.5b4.5b4.3b4.7b4.6b4.6b4.1b5.4b5.1b

Gross profit Margin, %

85%84%84%80%79%81%82%82%82%83%79%83%79%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

7.6b17.9b11.6b6.0b

Accounts Receivable

3.9b3.3b3.6b4.9b

Prepaid Expenses

1.7b1.6b1.4b2.0b

Inventories

801.0m814.0m922.0m1.7b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

10.3b8.7b11.5b7.6b13.2b14.6b16.9b11.2b9.5b10.1b6.7b12.9b4.1b

Accounts Receivable

4.0b4.5b4.1b3.8b3.5b3.5b3.3b3.4b3.3b3.9b3.2b3.9b3.9b

Prepaid Expenses

1.8b1.6b1.7b1.6b2.4b2.2b1.9b2.3b1.3b1.3b1.5b2.0b1.9b

Inventories

1.5b1.4b1.1b885.0m859.0m816.0m898.0m884.0m882.0m986.0m1.1b1.0b1.8b
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

4.6b5.5b5.4b89.0m

Depreciation and Amortization

1.3b1.4b1.4b1.5b

Inventories

(253.0m)(310.0m)(95.0m)(195.0m)

Accounts Payable

(430.0m)(39.0m)(61.0m)80.0m
USDQ1, 2017

Revenue/Employee

722.8k

Debt/Equity

1.3 x

Debt/Assets

0.5 x

Financial Leverage

2.8 x
Show all financial metrics

Gilead Sciences Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019Sep, 2020Dec, 2020

Countries

30353535

Patents (US)

642650

Phase III Trials Products

494127

Products

25272424
Show all operating metrics

Gilead Sciences Acquisitions / Subsidiaries

Company NameDateDeal Size
MYRDecember 10, 2020€1.15 b
ImmunomedicsSeptember 13, 2020$21 b
Forty SevenMarch 21, 2020$4.9 b
Cell Design LabsDecember 07, 2017$567 m
Kite PharmaAugust 28, 2017$11.9 b
Nimbus ApolloMay 17, 2016
EpitherapeuticsMay 06, 2015$65 m
Phenex PharmaceuticalsJanuary 06, 2015$470 m
YM BioSciencesFebruary 08, 2013$487.6 m
PharmassetNovember 21, 2011$11 b
Show more

Gilead Sciences Revenue Breakdown

Embed Graph

Gilead Sciences revenue breakdown by business segment: 98.5% from Product Sales and 1.5% from Other

Gilead Sciences revenue breakdown by geographic segment: 17.0% from Europe, 74.1% from United States and 8.9% from Other

Human Capital Metrics

Embed Graph
Show all human capital metrics

Gilead Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

F

56/100

SecurityScorecard logo

Gilead Sciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Gilead Sciences Online and Social Media Presence

Embed Graph

Gilead Sciences Company Culture

  • Overall Culture

    B+

    72/100

  • CEO Rating

    B

    72/100

  • Compensation

    A

    80/100

  • Diversity

    B

    71/100

Learn more on Comparably

Gilead Sciences News and Updates

Gilead Sciences, Inc Among Today’s Trending Stocks

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have dug up Gilead Sciences, Inc. among others.

Thinking about trading options or stock in Apple, Overstock.com, Generac Holdings, Gilead Sciences, or Carnival Corp?

NEW YORK, April 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, OSTK, GNRC, GILD, and CCL. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies

Application is based on Phase 2b/3 SELECTION study data with patients with moderately to severely active ulcerative colitis

The Links Foundation, Incorporated Awarded $350,000 Gilead Sciences Grant to Bolster Its Efforts to Eradicate the HIV Epidemic

Grant will be used to educate and help prevent the spread of the disease that disproportionately impacts Black women

Europe Cell and Gene Therapy Market Report 2021-2026: Prominent Players are Novartis, Spark Therapeutics, Amgen, Gilead Sciences & Organogenesis

Dublin, Feb. 15, 2021 (GLOBE NEWSWIRE) -- The "Europe Cell and Gene Therapy Market - Industry Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Europe Cell and Gene Thera…
Show more

Gilead Sciences Frequently Asked Questions

  • When was Gilead Sciences founded?

    Gilead Sciences was founded in 1987.

  • Who are Gilead Sciences key executives?

    Gilead Sciences's key executives are Daniel O’Day, Andrew Dickinson and William A. Lee.

  • How many employees does Gilead Sciences have?

    Gilead Sciences has 11,800 employees.

  • What is Gilead Sciences revenue?

    Latest Gilead Sciences annual revenue is $24.7 b.

  • What is Gilead Sciences revenue per employee?

    Latest Gilead Sciences revenue per employee is $2.1 m.

  • Who are Gilead Sciences competitors?

    Competitors of Gilead Sciences include Novo Nordisk, Catalent and Biogen.

  • Where is Gilead Sciences headquarters?

    Gilead Sciences headquarters is located at 333 Lakeside Dr, Foster City.

  • Where are Gilead Sciences offices?

    Gilead Sciences has offices in Foster City, El Segundo, Emeryville, Miami and in 41 other locations.

  • How many offices does Gilead Sciences have?

    Gilead Sciences has 45 offices.